Showing results (261-270 of 494) with videos related to

Sort By:
Pageof 50
Cancers|January 11, 2022
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive MelanomaAnna M Czarnecka, Krzysztof Ostaszewski, Aneta Borkowska, et al.
The American Journal of Surgical Pathology|July 9, 2025
DNA Methylation Profiling Separates SDH-Deficient GISTs From KIT-PDGFRA-Driven GISTs and Identifies Predictive Biomarkers for Targeted TherapyMałgorzata Chłopek, Jerzy Lasota, Omkar Singh, et al.
Current Oncology (Toronto, Ont.)|February 23, 2024
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal MelanomaKamil J Synoradzki, Natalia Paduszyńska, Malgorzata Solnik, et al.
The Lancet. Oncology|February 26, 2018
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Karl Lewis, Lev Demidov, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2015
Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinibChee Khoon Lee, David Goldstein, Emma Gibbs, et al.
Cancers|July 2, 2021
Efficacy and Safety of Hypofractionated Preoperative Radiotherapy for Primary Locally Advanced Soft Tissue Sarcomas of Limbs or Trunk WallHanna Koseła-Paterczyk, Paweł Teterycz, Mateusz J Spałek, et al.
Medical Oncology (Northwood, London, England)|July 11, 2014
Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applicationsJoanna Przybyl, Katarzyna Kozak, Hanna Kosela, et al.
Annals of Surgical Oncology|June 3, 2015
Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bonePiotr Rutkowski, Stefano Ferrari, Robert J Grimer, et al.
Cancers|October 29, 2020
Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern ImmunotherapyPawel Teterycz, Anna M Czarnecka, Alice Indini, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 7, 2021
Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter studySylvie Bonvalot, Jay Wunder, Alessandro Gronchi, et al.
Pageof 50